Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deciphering Genomic Complexity of Multiple Myeloma Using Optimized Optical Genome Mapping.

Hélène Guermouche1, Pauline Roynard1, Francesca Servoli1

  • 1Institute of Medical Genetics, Lille University Hospital, Lille, France.

The Journal of Molecular Diagnostics : JMD
|March 27, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
Same author

Genomic landscape of acute myeloid leukemia in adolescents and young adults.

Leukemia·2026
Same author

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Blood cancer journal·2026
Same author

Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.

British journal of haematology·2026
Same author

The t(X;5)(q13;q33) Translocation in Myeloid Neoplasms Is Preferentially Associated With Chronic Myelomonocytic Leukemia: A Report From the Groupe Francophone de Cytogénétique Hématologique.

Genes, chromosomes & cancer·2026
Same author

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Blood·2026
This summary is machine-generated.

This study introduces a new method for genomic analysis in multiple myeloma, enabling genome-wide insights from fewer cells. The optimized optical genome mapping approach improves diagnostic accuracy and patient stratification.

Area of Science:

  • Genomics
  • Hematology
  • Cancer Diagnostics

Background:

  • Routine multiple myeloma diagnostics rely on CD138+ plasma cell isolation and FISH analysis.
  • Current methods are limited by low cell yields, restricting genomic analysis scope.
  • Optical genome mapping (OGM) offers high-resolution genome-wide analysis but requires substantial cell numbers (1 million).

Purpose of the Study:

  • To develop an optimized OGM protocol for multiple myeloma diagnostics using limited CD138+ plasma cells.
  • To enhance the efficiency and scope of genomic evaluation in multiple myeloma.
  • To improve prognostic stratification for multiple myeloma patients through comprehensive genomic analysis.

Main Methods:

  • A novel strategy involving mixing CD138-positive and CD138-negative cell fractions was implemented.

Related Experiment Videos

  • Dilution experiments determined optimal mixing ratios for variant detection (50% CD138+ for structural variants, 24% for CNVs).
  • The optimized protocol was validated on 13 patient samples, comparing OGM results with fluorescence in situ hybridization (FISH).

    • Main Results:

    • A 50% CD138-positive cell mix was sufficient for detecting clonal structural and copy number variants.
    • A detection threshold of 24% for copy number variants was established.
    • OGM achieved 93% concordance with FISH for clonal anomalies and identified over 22 additional genomic variations.
    • The method consolidated multiple analyses, reduced material requirements, and detected critical prognostic anomalies.

    Conclusions:

    • The optimized OGM strategy effectively overcomes cell number limitations in multiple myeloma diagnostics.
    • This approach provides a more comprehensive genomic evaluation, enhancing prognostic accuracy.
    • The refined patient stratification aids in personalized treatment strategies for multiple myeloma.